FC
DGX icon

Farringdon Capital’s Quest Diagnostics DGX Stock Holding History

Farringdon Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,583
Closed -$310K – 257
2026
Q1 		$310K Buy
+1,583
New +$308K 0.07% 287
2025
Q3 		– Sell
-3,529
Closed -$634K – 495
2025
Q2 		$634K Buy
3,529
+1,186
+51% +$206K 0.21% 143
2025
Q1 		$396K Sell
2,343
-1,420
-38% -$233K 0.2% 140
2024
Q4 		$568K Buy
+3,763
New +$585K 0.23% 118

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Farringdon Capital's DGX Position: Q2 2026 in Review

Farringdon Capital sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 1,583 shares — an estimated $310K sold.

Farringdon Capital first reported a position in DGX in Q4 2024 and held it in 4 quarters. The position peaked at $634K in Q2 2025. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Farringdon Capital reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Farringdon Capital sold 1,583 Quest Diagnostics shares in Q2 2026, an estimated $310K.
  • Farringdon Capital first reported a position in Quest Diagnostics in Q4 2024 and held it in 4 quarters.
  • Farringdon Capital's Quest Diagnostics position peaked at $634K in Q2 2025.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Farringdon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.